In vitro Studies Using the Alpha-Emitter ²¹²Bi: Development of Therapy for Microscopic Carcinoma

Articles in the same Issue

1. Contents
2. PREFACE
3. Site-Specific Conjugation of Ethidium Homodimer to B72.3 mAb: Retention of Immunoreactivity, Isoelectric Point and in vivo Tumor Targeting
4. Lysine-Directed Conjugation of Ethidium Homodimer to B72.3 mAb: Retention of Immunoreactivity and Altered Tumor Targeting
5. Improving the Chemotherapeutic Index of IUdR Using a Vasoactive Immunoconjugate
6. Vascular Targeting for Radioimmunotherapy with ²¹³Bi
7. Ascorbic Acid Stabilization of Re-188- and I-131-Radiolabeled Peptides for Radiotherapy
8. Potential of the "[M(CO)₃]⁺" (M = Re, Tc) Moiety for the Labeling of Biomolecules
9. Direct Labeling of Antibodies IgG with Rhenium-186 Using Sodium Glucoheptonate
10. Convenient Synthesis and Bioevaluation of New MAG₃ Analogs for Rhenium-Labeling of Antibodies IgG
11. Rhenium-188-HEDP-kit Formulation and Quality Control
12. Radiopharmaceutical Design Using Novel Re-188 Imido Complexes
13. Stability of the Four 2-(p-nitrobenzyl)-trans-CyDTPA ⁸⁸Y Complexes
14. In vitro Studies Using the Alpha-Emitter ²¹²Bi: Development of Therapy for Microscopic Carcinoma
15. Enhancing the Specific Activity of ¹⁸⁶Re Using an Inorganic Szilard-Chalmers Process
16. Effect of Stoichiometric and Preparation Parameters on W-188/Re-188 Gel Generator Performance
17. An Improved Generator for the Production of ²¹³Bi from ²²⁵Ac
18. Optimizations of Radiolabeling of Immunoproteins with ²¹³Bi